58. 肥大型心筋症 Hypertrophic cardiomyopathy Clinical trials / Disease details

臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04133532 (ClinicalTrials.gov)	March 5, 2020	16/10/2019	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Drug: Metoprolol	University Hospital, Motol	NULL	Recruiting	18 Years	75 Years	All	50	Phase 4	Czechia
2	NCT03532802 (ClinicalTrials.gov)	May 1, 2018	19/4/2018	The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.	The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy.	Hypertrophic Cardiomyopathy	Drug: Metoprolol Succinate;Drug: Placebo oral capsule	Steen Hvitfeldt Poulsen	NULL	Completed	18 Years	N/A	All	30	Phase 2	Denmark
3	EUCTR2017-004478-32-DK (EUCTR)	10/01/2018	14/12/2017	The effect of metoprolol in hypertrophic obstructive cardiomyopathy	The effect of metoprolol on myocardial function, hemodynamics and heart failure symptoms in patients with hypertrophic obstructive cardiomyopathy - TEMPO	Hypertrophic obstructive cardiomyopathy MedDRA version: 20.0;Level: LLT;Classification code 10020876;Term: Hypertrophic obstructive cardiomyopathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Metoprololsuccinat INN or Proposed INN: metoprololsuccinat Other descriptive name: METOPROLOL SUCCINATE	Aarhus University Hospital	NULL	Not Recruiting			Female: yes Male: yes	32	Phase 2	Denmark